Original Publication Date: 1 February, 2016
Publication / Source: Pharmacogenomics
Authors: Thomas Schlange & Klaus Pantel
Despite the first reports of circulating cells from solid tumors shed light on the circulation in deceased and in living patients in 1869  and the mid 1950s , respectively, it took almost 50 years until the introduction of the CellSearch® system by Veridex (now Janssen Diagnostics, LLC, Raritan, NJ, USA) as well as its approval by the US FDA  in 2004 paved the way for widespread clinical assessment of the number of circulating tumor cells (CTCs) as a prognostic diagnostic tool.
Visit our Spotlight homepage now to discover more content hosted on Oncology Central as part of our Spotlight on circulating tumor cells.